Responses of Bone Turnover Markers and Bone Mineral Density to Growth Hormone Therapy in Ghildren with Isolated Growth Hormone Deficiency and Multiple Pituitary Hormone Deficiencies
- 1 January 2002
- journal article
- clinical trial
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 15 (6), 809-816
- https://doi.org/10.1515/jpem.2002.15.6.809
Abstract
Growth hormone deficiency (GHD) is an important cause of decreased bone mass in childhood and adolescence. The role of other pituitary hormone deficiencies on bone mass is still a query in children. Thirty-nine children (28 with isolated GHD [IGHD] and 11 with multiple pituitary hormone deficiency [MPHD]) were investigated to show the effects of IGHD vs MPHD on bone status. Bone turnover markers (calcium, phosphate, alkaline phosphatase [ALP] Bone ALP [BALP], osteocalcin [OSC], carboxyterminal propeptide of type-1 collagen [CPP-I], parathyroid hormone [PTH]) were measured before and every four months during growth hormone (GH) therapy; bone mineral density (BMD) of the lumbar spine was measured before and every six months during therapy. All bone turnover markers except calcium and PTH increased significantly during 1 year of GH therapy. There were no differences in the levels of bone turnover markers between children with IGHD and MPHD at baseline, and after 4, 8 and 12 months of therapy. Lumbar spine BMD SDS of all patients increased significantly during 1 year of therapy (p = 0.035 after 6 months and p <0.001 after 12 months compared with baseline). BMD SDS of both IGHD and MPHD groups were similar at baseline and after 6 and 12 months of therapy (p = 0.235, p = 0.295 and p = 0.384). Height SDS (HtSDS) at baseline was the most important predictor of baseline BMD SDS in children with GHD (t = 4.166, p <0.001). DeltaHtSDS was also positively related to deltaBMD SDS after 1 year of GH therapy. In conclusion, there was no difference in bone status of the patients with IGHD and MPHD at baseline. GH therapy yielded similar increases in bone mass in both groups. Increase in height contributed to increase in BMD during 1 year of GH therapy.Keywords
This publication has 17 references indexed in Scilit:
- Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with HypopituitarismJournal of Clinical Endocrinology & Metabolism, 1999
- Measurement of Volumetric Bone Mineral Density Accurately Determines Degree of Lumbar Undermineralization in Children with Growth Hormone DeficiencyJournal of Clinical Endocrinology & Metabolism, 1998
- Growth Hormone and BoneEndocrine Reviews, 1998
- Serum Bone Alkaline Phosphatase Isoenzyme Levels in Normal Children and Children with Growth Hormone (GH) Deficiency: A Potential Marker for Bone Formation and Response to GH TherapyJournal of Clinical Endocrinology & Metabolism, 1997
- Bone turnover and bone mineral density in young adult patients with panhypopituitarism before and after long-term growth hormone therapyActa Endocrinologica, 1995
- Consequences of childhood-onset growth hormone deficiency for adult bone massJournal of Bone and Mineral Research, 1994
- Reduced bone mineral density in patients with adult onset growth hormone deficiencyJournal of Clinical Endocrinology & Metabolism, 1994
- Bone mineral density and parameters of bone metabolism in patients with acromegalyJournal of Bone and Mineral Research, 1993
- Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onsetJournal of Clinical Endocrinology & Metabolism, 1992
- Bone mineral status in growth hormone deficiencyThe Journal of Pediatrics, 1980